Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
- 4 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 15 (1), 115-126
- https://doi.org/10.1007/s11523-020-00698-x
Abstract
Background Sorafenib represents one of the therapeutic strongholds for advanced hepatocellular carcinoma (HCC), but unfortunately, predictive factors are lacking. We previously reported that the VEGF single nucleotide polymorphisms (SNPs) rs2010963 and rs4604006 might correlate with clinical outcomes in sorafenib-treated HCC patients. Objective The objective of the ALICE-2 study is to define a prognostic angiogenesis profile to better identify HCC patients who are more likely to benefit from sorafenib treatment. Patients and methods From 2008 to 2015, all consecutive HCC patients receiving sorafenib according to the Italian label were tested for specific HIF-1α, VEGF, and VEGFR SNPs. Results from angiogenesis genotyping were then correlated with clinical outcome parameters. Results Globally, a total of 210 patients were enrolled. At multivariate analysis rs12434438 of HIF1α, rs2010963 of VEGF-A, and rs4604006 of VEGF-C were confirmed as independent predictive factors. At the combined analysis of significant SNPs, the presence of two favourable alleles of rs2010963 and rs4604006 of VEGF compared to only one or to none favourable alleles, was able to identify three separate patients populations with different time-to-progression (TTP) (10.8 vs. 5.6 vs. 3.7 months, respectively; p < 0.0001) and overall survival (OS) (19.0 vs. 13.5 vs. 7.5 months, respectively; p < 0.0001). Furthermore, the presence of the GG genotype of rs12434438 (HIF-1α) seemed able to select a population with a particularly poor outcome, independently from the clinical effect of the two VEGF SNPs (TTP: 2.6 months, HR: 0.54, p = 0.0374; OS: 6.6 months, p = 0.0061, HR: 0.43). Conclusions Our findings show that polymorphism analysis of HIF-1α, VEGF, and VEGFR genes may represent a prognostic panel to better identify HCC patients who are more likely to benefit from sorafenib treatment.Keywords
This publication has 35 references indexed in Scilit:
- The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell diseaseEuropean Journal of Haematology, 2012
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic optionsCancer Treatment Reviews, 2011
- Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF PolymorphismsPLOS ONE, 2011
- VEGF −460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinomaThe Pharmacogenomics Journal, 2010
- Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancerPharmacogenomics, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDSThorax, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003
- A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer riskInternational Journal of Cancer, 2003
- Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1Online Journal of Public Health Informatics, 1996